Huntleigh Advisors Inc. Purchases 4,753 Shares of Exagen Inc. $XGN

Huntleigh Advisors Inc. boosted its position in Exagen Inc. (NASDAQ:XGNFree Report) by 5.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,861 shares of the company’s stock after purchasing an additional 4,753 shares during the period. Huntleigh Advisors Inc. owned approximately 0.41% of Exagen worth $613,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Acadian Asset Management LLC bought a new stake in Exagen in the first quarter worth about $25,000. Institutional investors own 75.25% of the company’s stock.

Exagen Stock Performance

Exagen stock opened at $11.54 on Friday. The company has a market capitalization of $253.88 million, a PE ratio of -12.97 and a beta of 1.54. Exagen Inc. has a fifty-two week low of $2.38 and a fifty-two week high of $11.99. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.95 and a current ratio of 4.95. The company has a 50 day moving average price of $10.19 and a 200-day moving average price of $7.81.

Exagen (NASDAQ:XGNGet Free Report) last posted its earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%. Exagen has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Exagen Inc. will post -0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on XGN shares. Canaccord Genuity Group raised their price objective on shares of Exagen from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, July 30th. Craig Hallum initiated coverage on shares of Exagen in a research note on Wednesday, July 23rd. They set a “buy” rating and a $12.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, October 8th. B. Riley initiated coverage on shares of Exagen in a research note on Thursday, September 11th. They set a “buy” rating and a $15.00 price target for the company. Finally, KeyCorp lifted their price target on shares of Exagen from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Exagen currently has an average rating of “Moderate Buy” and a consensus price target of $12.60.

Read Our Latest Report on XGN

Exagen Company Profile

(Free Report)

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Further Reading

Institutional Ownership by Quarter for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.